Regeneron posts positive data on Eylea Ph III; Growing Hyperion to move into new digs;

@FierceBiotech: ICYMI last week: FierceMedicalDevices' 2013 Fierce 15. Feature | Follow @FierceBiotech

@JohnCFierce: Latest biotech IPO tally: 39 done, 15 in the queue--report updated with stock performance as of last Thursday. Feature | Follow @JohnCFierce

@DamianFierce: Quintiles is shuttering an early-phase Indian facility as regulatory hurdles make times tough. FierceCRO article | Follow @DamianFierce

@EmilyMFierce: is looking for an associate editor. Details here | Follow @EmilyMFierce

> Regeneron ($REGN) is on a roll. After posting promising data from its first-of-many Phase III studies for its PCSK9 drug, the biotech reports that its late-stage study of the eye drug Eylea in patients with vision loss caused by blood clots in retinal veins proved positive. The treatment is already approved for wet age-related macular degeneration. Story

> Fast-growing Hyperion Therapeutics ($HPTX) says it plans to move into a new, expanded headquarters space. Story

Medical Device News

@FierceMedDev: Cheney worried defibrillator was vulnerable to hacking from terrorists. Item | Follow @FierceMedDev

@MarkHFierce: Kona Medical, a 2013 Fierce 15 winner, drew in $10M in new funding to hit China with its renal denervation device. Release | Story | Follow @MarkHFierce

@MichaelGFierce: ICYMI: AstraZeneca teams with Taris to research bladder cancer delivery device. Story from FierceDrugDelivery | Follow @MichaelGFierce

> DoD ponies up $15M to develop Terumo's blood-cleaning tech. News

> Bard recalls vascular stent due to deployment malfunction risks. Story

> Medtronic launches clot-removal tech in U.S. Article

Pharma News

@FiercePharma:  ICYMI, most popular special report this weekend: Top 15 Drug Launch Superstars | Follow @FiercePharma

@EricPFierce: Novartis' Sandoz is the 2nd largest generics maker in the world. It targets biosimilars to stay there. More | Follow @EricPFierce

@CarlyHFierce: We now present: Top 10 generics makers by 2012 revenue. Special report | Follow @CarlyHFierce

> Regeneron and Bayer's Eylea turns out positive BRVO trial data. Story

> India's bargain-priced cancer drugs lure Chinese smugglers. Article

> Japan's Eisai says U.K. cost watchdogs must open up--or else. Report

CRO News

> WuXi is first in China with CLIA-OK genomics lab. Item

> Novella teams with Scioderm for 'breakthrough' drug. More

> DrugDev picks up CFS Clinical for trial software. Story

> Aenova snags Haupt to boost CMO presence. News

> Clinlogix buys German CRO with eye on Euro demand. Article

Biotech IT News

> Pfizer and Roche back protein shape change monitoring startup. Story

> Deloitte unveils another EHR-driven software tool. News

> Statisticians fret over misuse of data-crunching software. More

> Veeva stock soars following successful IPO. Article

> Roche to shutter 454, 6 years after buying NGS business. Story

And Finally… Consumer advocates say that special regulatory provisions should be put in place to increase the number of minorities involved in clinical research studies. Release

Suggested Articles

Biogen stunned the biotech world Tuesday when it said it would file aducanumab for approval. Now that the dust has settled, what are analysts saying?

Biocytogen uses chromosome engineering for the in situ replacement of mouse antibody genes with the human counterparts.

Eli Lilly is canning the lead program for the crown jewel of its $1.6 billion Armo buyout after the drug put up a poor showing in pancreatic cancer.